Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel
| Autor: | Geoffrey L. Hammond, Simo Nummi, M. S. Langley, Leif Lund, Philip Robinson |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Adult
medicine.medical_specialty Norpregnenes medicine.medical_treatment Radioimmunoassay Biological Availability Levonorgestrel Pharmacology Ethinyl Estradiol Steroid Oral administration Desogestrel Internal medicine Sex Hormone-Binding Globulin Medicine Endocrine system Humans Testosterone Serum Albumin Transcortin business.industry Norgestrel Obstetrics and Gynecology Bioavailability Contraceptives Oral Combined Endocrinology Reproductive Medicine Female business hormones hormone substitutes and hormone antagonists Hormone medicine.drug Contraceptives Oral |
| Zdroj: | Fertility and sterility. 42(1) |
| ISSN: | 0015-0282 |
| Popis: | The oral administration of 150 micrograms desogestrel and 30 micrograms ethinyl estradiol (EE2) increases (P less than 0.001) serum concentrations of sex-hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG), whereas treatment with 150 micrograms levonorgestrel and 30 micrograms EE2 only increases serum CBG concentrations. No changes in serum albumin concentrations occurred during or after treatment with either preparation, and increases in SHBG and CBG returned to the pretreatment values 1 month after treatment ceased. The serum distribution of levonorgestrel was unchanged during treatment, whereas the increase in serum SHBG concentrations after treatment with the preparation containing desogestrel decreased (P less than 0.001) the percentage of non-protein-bound 3-keto- desogestrel and the percentage of albumin-bound 3-keto- desogestrel but increased (P less than 0.001) the SHBG-bound fraction. Oral contraceptives containing either progestogen decrease the mean serum non-protein-bound testosterone concentrations, especially during treatment with desogestrel (P less than 0.001), and desogestrel may therefore by the more appropriate progestogen for the treatment of women prone to androgenic side effects.The oral administration of 150 mcg desogestrel and 30 mcg ethinly estradiol (EE2) increases (P0.001) serum concentrations of sex hormone binding globulind (SHBG) and corticosteroid-binding globulin (CBG) whereas treatment with 150 mcg levonorgestrel and 30 mcg EE2 only increases serum CBG concentrations. No changes in serum albumin concentrations occurred during or after treatment with either preparation, and increases in SHBG and CBG returned to the pretreatment values 1 month after treatment ceased. The serum distribution of levonorgestrel was unchanged during treatment, whereas the increase in serum SHBG concentrations after treatment with the preparation containing desogestrel decreased (P0.001) the percentage of nonprotein-bound 3-keto-desogestrel and the precentage of albumin-bound 3-ketodesogestrel but increased (P0.001) the SHBG-bound fraction. Oral contraceptives containing either progestogen decrease the mean serum nonprotein-bound testosterone concentratious, especially during treatment with desogesgtrel (P0.001), and desogestrel may therefore be the more appropriate progestogen for the treatment of women who are prone to androgenic side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|